- Previous Close
0.2588 - Open
0.2680 - Bid 0.1967 x 200
- Ask 0.3469 x 200
- Day's Range
0.2624 - 0.2871 - 52 Week Range
0.2400 - 4.8100 - Volume
262,974 - Avg. Volume
934,736 - Market Cap (intraday)
9.493M - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6500 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.87
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
www.relmada.comRecent News: RLMD
View MorePerformance Overview: RLMD
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RLMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RLMD
View MoreValuation Measures
Market Cap
8.59M
Enterprise Value
-36.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.24
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-73.14%
Return on Equity (ttm)
-132.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-79.98M
Diluted EPS (ttm)
-2.6500
Balance Sheet and Cash Flow
Total Cash (mrq)
44.91M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-23.85M